Management ChangeApr 28, 2026, 04:21 PM
LABT Appoints Joseph Tucker, Ph.D., to Board of Directors
AI Summary
Lakewood-Amedex Biotherapeutics Inc. (LABT) announced the appointment of Dr. Joseph Tucker to its Board of Directors, effective April 24, 2026. Dr. Tucker, currently CEO of Enveric Biosciences Inc., brings over two decades of leadership experience in public and private biotechnology companies, including expertise in capital markets and drug development. This strategic appointment aims to strengthen LABT's governance and strategic capabilities following its recent Nasdaq direct listing, as the company advances its growth strategy and its Bisphosphocin® class antimicrobials.
Key Highlights
- Dr. Joseph Tucker appointed to Lakewood-Amedex Biotherapeutics Inc. (LABT) Board of Directors, effective April 24, 2026.
- He will serve until the Company’s 2027 annual meeting of stockholders.
- Dr. Tucker, age 57, is currently Chief Executive Officer and Director of Enveric Biosciences Inc. (NASDAQ: ENVB).
- He has over two decades of leadership experience in public and private biotech companies.
- Previously served as CEO/Director at Willow Biosciences Inc. (TSX: WLLW) and Stem Cell Therapeutics Corp. (TSX: SSS).
- He has raised over $100 million in capital and executed numerous partnerships.
- The appointment strengthens the Board following LABT's recent Nasdaq direct listing.
Price Impact
More from LABT